|
|
Scientific
Session...
October
16, 2000
|
|
9.20 a.m.
|
WELCOME
V. Silingardi, U. Torelli
|
|
9.30 a.m.
|
INTRODUCTION
S. Sacchi
|
|
9.40 a.m.
|
BIOLOGICAL
OVERVIEW Chairmen:
G. Pizzolo, B. Falini
-Myeloid- and B-antigens as a target of immunotherapy.
L. Baldini
-Rituximab mechanisms of action. M. Introna
-Clinical pharmacokinetic of Rituximab. M.
Regazzi
-Radiolabeled monoclonal antibody: mechanisms of action.
M.S. Kaminski
-CD33 antibody mediated chemotherapy: Laboratory studies
on the in vivo effectivness of CMA-676. J.J.M. Van
Dongen
|
|
11.40 a.m.
|
Coffe Break
|
|
12.00 a.m.
|
-CD30 molecule as a target
antigen for immunotherapy. B.
Falini
Panel discussion
chaired by G. Pizzolo and B. Falini:
Issues
and new approaches with conjugate and unconjugate monoclonal
antibodies
|
|
1.00 p.m.
|
Lunch
|
|
2.15 p.m.
|
MONOCLONAL
ANTIBODY THERAPY I
Malignant
lymphoma.
Chairmen: A. Pileri, S. Tura
-Rituximab in combination with chemotherapy. P.L.
Zinzani
-Rituximab in combination with biological response
modifiers. S. Sacchi
-Radioimmunotherapy with I131-labeled anti CD20
monoclonal antibody. M.S. Kaminski
-Radioimmunotherapy with Y90-labeled anti CD20
monoclonal antibody. L.I. Gordon
|
|
4.15 p.m.
|
Coffe Break
|
|
4.30 p.m.
|
-Rituximab in the
treatment of mantle-cell lymphoma. J.M. Foran
-High dose chemotherapy and in-vivo purging with
Rituximab. C. Tarella
-The true relevance of molecular remission in follicular
lymphoma. G. Saglio
|
|
6.00 p.m.
|
Panel
discussion chaired by
M. Brugiatelli and G.L. Castoldi:
Monoclonal
antibodies therapy in NHL: is the future
here?
|
|
|
|